Why the study?
Does oral hydralazine improve coronary blood flow and myocardial energetics in patients with chronic nonischemic congestive heart failure?
Population
10 patients with chronic nonischemic congestive heart failure, mean age 48 years, 50% male. Key inclusion…
Comparison
Oral hydralazine 1 mg/kg single dose vs Baseline measurements
Design
Cohort
Follow-up
4 hours
Key result
Oral hydralazine acutely increased coronary blood flow from 144 to 218 ml/min and decreased coronary vascular resistance from 0.55 to 0.36 mm Hg/ml/min in nonischemic heart failure (p<0.01).
Authors
Loading...
Hydralazine may augment coronary perfusion in nonischemic HF; leaves open whether this alters outcomes or energetics in RCTs.
Does oral hydralazine improve coronary blood flow and myocardial energetics in patients with chronic nonischemic congestive heart failure?
Absolute Event Rate: 218% vs 144%
p-value: p=<0.01
In patients with severe nonischemic heart failure, acute administration of oral hydralazine significantly increases coronary blood flow and decreases coronary vascular resistance, improving the myocardial oxygen supply-demand ratio despite increased oxygen consumption.
Magorien et al. (1982) studied chronic nonischemic congestive heart failure (n=10). oral hydralazine vs. baseline was evaluated on coronary blood flow (p=<0.01). Oral hydralazine acutely increased coronary blood flow from 144 to 218 ml/min and decreased coronary vascular resistance from 0.55 to 0.36 mm Hg/ml/min in nonischemic heart failure (p<0.01).